275.4 ð ç« æ«éèš Summary
275.4.1 ð äžå¥è©±çžœçµ
å¿èåŸ©å¥ (CR) æ¯ post-ACS / CABG / HF / ç£èè¡åŸ / LVAD / PAD / HCM ç Class I 建è°ïŒæŽåéåèšç·Žãè¥ç©åªåãå±éªå åæ§å¶ãå¿çæ¯æãè¡æäºå€§æ¯æ±ïŒCochrane 2021 meta-analysis 顯瀺 â å šå æ»äº¡ç 17%ãâ CV æ»äº¡ 22%ãâ äœé¢ç 26%ïŒäœç®åèœä»ç < 30%ã宿ç < 10%ïŒhybrid + tele-rehab çºæªäŸè¶šå¢ã
275.4.2 ð æ²»ç粟èŠ
- éåèæ¹ïŒaerobic 150 min/wk moderateïŒæ 75 min/wk vigorousïŒ+ resistance 2-3x/wk
- 匷床ïŒ60-80% HRmax æ Borg RPE 12-14
- äžå€§é段ïŒPhase I (äœé¢æ) â Phase II (12 é±éèšºç£æž¬åŒ 36 sessions) â Phase III (瀟åé·æç¶æ)
- æŽåïŒå°äžæµ·é£²é£ + æèž + æ§ç³æ§å£æ§è + GDMT åªå + CBT å¿çæ¯æ
275.4.3 ð¯ ç§é«åž«çèåæé
- Class I 建è°ïŒpost-ACS within 12 mo, post-PCI/CABG, stable CCS, HFrEF + HFpEF, valve surgery/TAVR, transplant, LVAD, PAD, HCM
- HF-ACTION 2009 + REHAB-HF 2021ïŒHFrEF + HFpEF éœæ CR çè
- 150 min/é± äžåŒ·åºŠ OR 75 min/é± é«åŒ·åºŠïŒWHO + AHAïŒ
- HIIT åšç©©å® CAD å®å š (SAINTEX-CAD)
- èœä»çæ 30%ã宿çäžå° 10% â æš automatic referral + hybrid/tele-rehab
- æèžæ¯ single best intervention â post-MI mortality â 36%
- HCM ä¹é©åäžåŒ·åºŠéåïŒ2024 ACC/AHA + LIVE-HCM 2023ïŒâ æ¹å¯«èæçŠå¿
- frailty + CR åšè幎ç¹å¥éèŠïŒlower intensity, longer duration, sarcopenia ä»å ¥